WHO Committee Recommends Limited Use Of Sanofi’s Dengue Vaccine

STAT: Experts call for use of Sanofi’s dengue vaccine to be halted in most cases
“The use of the world’s first dengue vaccine should be temporarily suspended except in limited circumstances because of concerns that it could put some people at heightened risk of severe disease, according to prominent public health experts. … The experts, who include the co-chair of a technical group that advised the World Health Organization on the vaccine, said only people known to have contracted the disease — that is, those whose medical records confirm previous infection — should be offered the vaccine at this time…” (Branswell, 12/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.